Next |
home / stock / apre / apre message board
Subject | By | Source | When |
---|---|---|---|
Dropping like a waterfall. | willlbone | investorshub | 11/11/2022 4:07:04 PM |
$APRE is climbing, it climbed today in spite | Nazirite | investorshub | 07/11/2022 8:22:41 PM |
Price target set for $3 buy and hold | Nazirite | investorshub | 07/11/2022 1:25:09 PM |
GM $APRE time to work | Nazirite | investorshub | 07/11/2022 12:51:35 PM |
High volume today 43x avg | Nazirite | investorshub | 07/08/2022 3:52:16 PM |
$APRE PT $3 can we see | Nazirite | investorshub | 07/08/2022 3:50:50 PM |
Hot Day for $APRE | Nazirite | investorshub | 07/08/2022 2:26:46 PM |
Aprea Therapeutics shares are trading higher after Wedbush | Nazirite | investorshub | 07/08/2022 2:21:47 PM |
Very strong! | subslover | investorshub | 07/08/2022 12:46:20 PM |
Why? Any insider good news? | stockforce | investorshub | 07/07/2022 12:48:19 AM |
Im joining in | MonopolyTrader | investorshub | 07/06/2022 11:11:08 PM |
coming off 53w low 1.46 just on thursday | TheFinalCD | investorshub | 02/28/2022 4:33:39 PM |
$APRE 8 Catalyst on the way not including | Jimmy Quick | investorshub | 10/14/2021 3:06:03 PM |
Aprea Therapeutics, Inc. (NASDAQ: $APRE): Phase 1/2 study | crudeoil24 | investorshub | 09/20/2021 11:45:49 AM |
On heavy watch for Monday. | dinogreeves | investorshub | 09/19/2021 4:38:56 AM |
If the Monday data can be very promising, | stockforce | investorshub | 09/17/2021 9:13:20 PM |
This could get some nice legs over 6+, | DailyX | investorshub | 09/17/2021 8:36:21 PM |
Good luck to all! Looks very promising! | stockforce | investorshub | 09/17/2021 8:10:26 PM |
Something special going on here with the gap | NATURES WAY | investorshub | 07/24/2021 6:39:02 PM |
CASH ON HAND $77 MILLION | Jimmy Quick | investorshub | 06/23/2021 2:23:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
2024-05-16 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 c...
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmac...